Author

Albrecht Stenzinger

Observed names: A Stenzinger, A. Stenzinger, Albrecht Stenzinger (Heidelberg), Stenzinger, Albrecht

Institutions: German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, German Center for Lung Research, Deutsches Konsortium für Translationale Krebsforschung

Observed institutions: AstraZeneca (United Kingdom), The University of Sydney, Harvard University, German Cancer Research Center, University of Cologne, Justus-Liebig-Universität Gießen, Heidelberg University, Royal North Shore Hospital, Bundesministerium für Forschung, Technologie und Raumfahrt, University Hospital Heidelberg, Massachusetts General Hospital, University Medical Center of the Johannes Gutenberg University Mainz, Roche Pharma AG (Germany), University Hospital Zurich, National Center for Tumor Diseases, Essen University Hospital, German Center for Lung Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Gallagher (United States), Deutsches Konsortium für Translationale Krebsforschung, German Cancer Consortium (DKTK) Dresden, Charité – Universitätsmedizin Berlin, Ludwig-Maximilians-Universität München, Macquarie University

ORCID: 0000-0003-1001-103X

Observed ORCID: 0000-0003-1001-103X

OpenAlex ID: A5026607584

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

2018 · T.A. Chan, M. Yarchoan, et al. · Annals of Oncology · 2,654

PDF

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

2020 · F. Mosele, J. Remon, et al. · Annals of Oncology · 1,201

PDF

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

2013 · Irène Baccelli, Andreas Schneeweiss, et al. · Nature Biotechnology · 1,050

Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors

2020 · Dan Sha, Zhaohui Jin, et al. · Cancer Discovery · 865

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 · A. Vogel, J. Bridgewater, et al. · Annals of Oncology · 744

PDF

The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival

2012 · Arne Warth, Thomas Muley, et al. · Journal of Clinical Oncology · 699

SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

2021 · Janis A. Müller, Rüdiger Groß, et al. · Nature Metabolism · 555

PDF

Sarcoma classification by DNA methylation profiling

2021 · Christian Koelsche, Daniel Schrimpf, et al. · Nature Communications · 539

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

2020 · Diana M Merino, Lisa M McShane, et al. · Journal for ImmunoTherapy of Cancer · 516

PDF

Accurate and efficient detection of gene fusions from RNA sequencing data

2021 · Sebastian Uhrig, Julia Ellermann, et al. · Genome Research · 513

PDF

Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment

2019 · Patrick Schelb, Simon Kohl, et al. · Radiology · 328

Integrative genomic and transcriptomic analysis of leiomyosarcoma

2018 · Priya Chudasama, Sadaf S. Mughal, et al. · Nature Communications · 303

PDF

The landscape of metastatic progression patterns across major human cancers

2014 · Jan Budczies, Moritz von Winterfeld, et al. · Oncotarget · 302

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

2021 · Peter Horak, Christoph Heining, et al. · Cancer Discovery · 297

Automated sample preparation with SP3 for low‐input clinical proteomics

2020 · Torsten Müller, Mathias Kalxdorf, et al. · Molecular Systems Biology · 288

Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer

2013 · B Goeppert, L Frauenschuh, et al. · British Journal of Cancer · 271

PDF

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

2021 · Khalid El Bairi, Harry R. Haynes, et al. · npj Breast Cancer · 270

PDF

Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)

2022 · Peter Horak, Malachi Griffith, et al. · Genetics in Medicine · 264

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

2018 · Christoph Heining, Peter Horak, et al. · Cancer Discovery · 240

Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions

2019 · Albrecht Stenzinger, Jeffrey D. Allen, et al. · Genes Chromosomes and Cancer · 239

PDF

Homologous Recombination Deficiency: Concepts, Definitions, and Assays

2022 · Mark D Stewart, Diana Merino Vega, et al. · The Oncologist · 237

PDF

Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach

2012 · Stephan Wienert, Daniel Heim, et al. · Scientific Reports · 236

PDF

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma

2016 · Elisa M Noll, Christian Eisen, et al. · Nature Medicine · 219

PDF

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis

2012 · Felix Sahm, David Capper, et al. · Blood · 219

Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells

2014 · Norman Ertych, Ailine Stolz, et al. · Nature Cell Biology · 216

Works count: 899

Citation count: 30,420

H-index: 82

I10-index: 379